title: Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab.
abstract: This study was aimed to analyse the prevalence of antinuclear antibodies in patients with psoriasis after treatment with infliximab and correlates the development of antibodies with both response to treatment and adipokines levels. Serum levels of ANA, anti-dsDNA, anti-histone, anti-nucleosome and anti-ENA antibodies at baseline after 2 and 12 months of treatment with infliximab were measured in 27 patients with psoriasis, as well as in 27 matched controls. Serum C-reactive protein (CRP), chemerin, visfatin and resistin were also assessed. The prevalence of ANA increased from 22 to 37% and 63% (p < 0.01) during treatment with infliximab, with a gradual progressive increase both in ANA titre and in percentage of ANA pattern. The prevalence of other antibodies also increased from 7 to 30% and 48% (p < 0.01) for anti-ds-DNA and from 7 to 26% and 37% for anti-nucleosome antibodies (p < 0.05), whereas the prevalence of anti-histone and anti-ENA antibodies was unchanged throughout the study period. Basal chemerin, resistin and CRP levels were higher in patients than in controls, and their levels progressively normalized during treatment (p < 0.01). Conversely, visfatin levels gradually increased (p < 0.01). ANA+ patients tended to show a faster decrease in PASI score, CRP and chemerin levels after 2 months, but the PASI score did not differ between ANA+ and ANA- patients at 12 months. A higher increase of visfatin was also found in ANA+ patients at 2 and 12 months. The antinuclear antibody response induced by infliximab was restricted to ANA, anti-dsDNA and anti-nucleosome antibodies. Patients who developed ANA positivity showed a faster clinical, inflammatory and immunological response to infliximab therapy.
authors.affiliation: Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
authors.forename: Viviana
authors.initials: V
authors.lastname: Lora
authors.forename: Chiara
authors.initials: C
authors.lastname: Bonaguri
authors.forename: Paolo
authors.initials: P
authors.lastname: Gisondi
authors.forename: Franca
authors.initials: F
authors.lastname: Sandei
authors.forename: Luisita
authors.initials: L
authors.lastname: Battistelli
authors.forename: Annalisa
authors.initials: A
authors.lastname: Russo
authors.forename: Alessandra
authors.initials: A
authors.lastname: Melegari
authors.forename: Tommaso
authors.initials: T
authors.lastname: Trenti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lippi
authors.forename: Giampiero
authors.initials: G
authors.lastname: Girolomoni
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000974:Antibodies, Antinuclear / Q000097:blood; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000378:metabolism; D018925:Chemokines / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D052243:Resistin / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D018925:Chemokines; D036341:Intercellular Signaling Peptides and Proteins; C478630:RARRES2 protein, human; D052243:Resistin; D002097:C-Reactive Protein; D000069285:Infliximab; D054409:Nicotinamide Phosphoribosyltransferase